Bath Savings Trust Co Decreases Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Bath Savings Trust Co trimmed its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 20.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,465 shares of the medical instruments supplier’s stock after selling 369 shares during the quarter. Bath Savings Trust Co’s holdings in West Pharmaceutical Services were worth $440,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Fidelis Capital Partners LLC bought a new position in West Pharmaceutical Services during the 1st quarter valued at about $27,000. Crewe Advisors LLC grew its holdings in West Pharmaceutical Services by 322.7% during the 2nd quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 71 shares during the last quarter. Quarry LP grew its holdings in West Pharmaceutical Services by 155.3% during the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares during the last quarter. Hazlett Burt & Watson Inc. bought a new position in West Pharmaceutical Services during the 1st quarter valued at about $40,000. Finally, Northwest Investment Counselors LLC bought a new position in West Pharmaceutical Services during the 1st quarter valued at about $40,000. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Stock Performance

Shares of NYSE:WST opened at $286.48 on Wednesday. The company has a market capitalization of $20.78 billion, a price-to-earnings ratio of 37.79, a PEG ratio of 10.57 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70. The firm’s 50-day moving average is $301.18 and its 200 day moving average is $330.18. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The company had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. West Pharmaceutical Services’s revenue was down 6.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.11 earnings per share. Research analysts predict that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current year.

Insiders Place Their Bets

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the transaction, the vice president now directly owns 1,478 shares in the company, valued at $443,400. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.53% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.